Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes

Experimental and Molecular Medicine

Volumn 36, Issue 1, 2004, Pages 65-70

  Lee, Eun Young ^a   Shim, Myung Sook ^b   Kim, Mi Jin ^c   Hong, Sae Yong ^a   Shin, Young Goo ^b   Chung, Choon Hee ^b  

^a Soonchunhyang University   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

Author keywords

Angiotensin II receptor blocker; Diabetes mellitus; Diabetic nephropathy; Podocyte; Vascular endothelial growth factor

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; STREPTOZOCIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENE EXPRESSION; GLOMERULUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MACROMOLECULE; MALE; NONHUMAN; PATHOGENESIS; PODOCYTE; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA; GLOMERULUS;

EID: 1642358301     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2004.9     Document Type: Article

References (24)

1. Blantz RC, Gabbai FB. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient. Kidney Int Suppl 1987;20:S108-11
2. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 1973;34:279-82
3. Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK, Won NH. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 2000;77:S104-12
4. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48:2229-39
5. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993-1000
6. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000;43:1360-7
7. Ha SW, Seo YK, Kim JG, Kim IS, Sohn KY, Lee BH, Kim BW. Effect of high gulcose on synthesis and gene expression of collagen and fibronectin in cultured vascular smooth muscle cells Effect of high gulcose on synthesis and gene expression of collagen and fibronectin in cultured vascular smooth muscle cells. Exp Mol Med 1997;29:59-64
8. Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 2002;290:177-84
9. Kretzler M, Schroppel B, Merkle M, Huber S, Mundel P, Horster M, Schlondorff D. Detection of multiple vascular endothelial growth factor splice isoforms in single glomerular podocytes. Kidney Int Suppl 1998;67:S159-61
10. Kriz W, Hackenthal E, Nobiling R, Sakai T, Elger M, Hahnel B. A role for podocytes to counteract capillary wall distension. Kidney Int 1994;45:369-76
11. Lane PH, Steffes MW, Mauer SM. Estimation of glomerular volume: a comparison of four methods. Kidney Int 1992;41:10851089
12. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000;77:S93-8
13. Lynch KM, Sellers TS, Gossett KA. Evaluation of an automated pyrogallol red-molybdate method for the measurement of urinary protein in rats. Eur J Clin Chem Clin Biochem 1996;34:569-71
14. Mundel P, Kriz W. Structure and function of podocytes: an update. Anat Embyol (Berl) 1995;192:385-97
15. Nagisa Y, Shintani A, Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia 2001;44:883-8
16. Nelson RG, Meyer TW, Myers BD, Bennett PH. Clinical and pathological course of renal disease in non-insulin-dependent diabetes mellitus: the Pima Indian experience. Semin Nephrol 1997;17:124-31
17. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998;82:619628
18. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW, Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342-8
19. Parving HH, Kastrup J, Smidt UM. Reduced transcapillary escape of albumin during acute blood pressure-lowering in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 1985;28:797-801
20. Pavenstadt H. Franz Volhard Award 2000: angiotensin II signalling in the podocyte. Kidney Blood Press Res 2000;23:156-8
21. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;21:1787-92
22. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999;42:579-88
23. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995;25:913-7
24. Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Miner Electrolyte Metab 1998;24:400-5